1. Home
  2. USGO vs PYXS Comparison

USGO vs PYXS Comparison

Compare USGO & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USGO

U.S. GoldMining Inc.

HOLD

Current Price

$10.58

Market Cap

174.3M

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$1.78

Market Cap

172.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USGO
PYXS
Founded
2015
2018
Country
United States
United States
Employees
10
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.3M
172.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
USGO
PYXS
Price
$10.58
$1.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$30.75
$7.00
AVG Volume (30 Days)
51.0K
650.1K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.42
$0.97
52 Week High
$17.98
$5.55

Technical Indicators

Market Signals
Indicator
USGO
PYXS
Relative Strength Index (RSI) 33.74 43.73
Support Level $10.22 $1.23
Resistance Level $11.20 $2.27
Average True Range (ATR) 0.59 0.30
MACD -0.33 -0.08
Stochastic Oscillator 16.19 4.62

Price Performance

Historical Comparison
USGO
PYXS

About USGO U.S. GoldMining Inc.

US Goldmining Inc is a mineral exploration company with a focus on the exploration and development of a project located in Alaska, USA. The company's primary asset is the 100%-owned Whistler exploration property located in Alaska, USA. It operates and reports in one segment, which focuses on the exploration and development of mineral properties.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: